4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021
August 02 2021 - 6:00AM
Business Wire
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical
company leading the development of Live Biotherapeutic products
(LBPs), a novel class of drug derived from the microbiome, today
announces two poster presentations at the European Society for
Medical Oncology (ESMO) Congress, held from September 16-21, 2021.
The two e-posters will be available from 07:30 BST (02:30 ET) on
September 16, 2021.
Poster presentation details are as follows:
Presentation Title: Baseline biomarkers associated with
clinical benefit in patients with solid tumors refractory to immune
checkpoint inhibitors (ICIs) treated with live biotherapeutic
MRx0518 in combination with pembrolizumab Presenting Author:
Dr. Edwin R. Parra, Assistant Professor, Department of
Translational Molecular Pathology, University of Texas MD Anderson
Cancer Center Presentation Number: 1024P
Presentation Title: Neoadjuvant MRx0518 treatment is
associated with significant gene and metagene signature changes in
solid tumours Presenting Author: Dr. Mark P. Lythgoe,
Academic Clinical Fellow in Medical Oncology and Pharmacist,
Imperial College London Presentation Number: 543P
About MRx0518
MRx0518 is single strain Live Biotherapeutic product in
development for the treatment of cancer. It is delivered as an oral
capsule and stimulates the body’s immune system, directing it to
produce cytokines and immune cells that are known to attack tumors.
It is currently being evaluated in three clinical trials in cancer
patients. MRx0518-I-001 is a neoadjuvant monotherapy study in a
variety of solid tumors and is being conducted at Imperial College
(London, UK). MRx0518-I-002 is in combination with KEYTRUDA
(pembrolizumab) in patients who have previously progressed on anti
PD-1 therapies. The Coordinating Investigator of the study is at
The University of Texas MD Anderson Cancer Center, Houston, USA,
with multiple additional sites in the US. The study is being
conducted in collaboration with MSD, the tradename of Merck &
Co., Inc., Kenilworth, NJ, USA. MRx0518-I-003 is in combination
with preoperative radiotherapy in resectable pancreatic cancer. A
fourth clinical trial, in collaboration with Merck KGaA and Pfizer
Inc., of BAVENCIO (avelumab) in combination with MRx0518 as a
first-line maintenance therapy for patients with locally advanced
or metastatic urothelial carcinoma that has not progressed with
first-line platinum-containing chemotherapy, is expected to
commence in Q4 2021.
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D has developed a proprietary platform,
MicroRx®, that rationally identifies Live Biotherapeutics based on
a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has five clinical programs,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumors, a Phase I study
of MRx0518 in patients with pancreatic cancer, a Phase I/II study
of MRx-4DP0004 in asthma, and Blautix® in Irritable Bowel Syndrome
(IBS) which has completed a successful Phase II trial.
Preclinical-stage programs include candidates for CNS disease such
as Parkinson's disease and other neurodegenerative conditions. The
Company has a research collaboration with MSD, a tradename of Merck
& Co., Inc., Kenilworth, NJ, USA, to discover and develop Live
Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210802005047/en/
4D pharma Investor Relations ir@4dpharmaplc.com
Singer Capital Markets - Nominated Adviser and Joint Broker +44
(0)20 7496 3000 Philip Davies / Iqra Amin / James Fischer
(Corporate Finance) Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500 Dominic Wilson / Phil Walker
Stern Investor Relations, Inc. +1-212-362-1200 Julie Seidel
Julie.seidel@sternir.com
Image Box Communications +44 (0)20 8943 4685 Neil Hunter /
Michelle Boxall neil@ibcomms.agency / michelle@ibcomms.agency
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2024 to May 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From May 2023 to May 2024